FDA
-
-
-
-
-
-
-
Immunome doses first patient in Phase 1 trial of IM-1617 cancer drug
-
-
-
-
-
-
-
Immunome submits drug application to FDA for desmoid tumor treatment
-
-
-
-
-
-
-
Immunome Inc. (IMNM) PT Raised to $35 at Guggenheim
-
-
-
-
-
-
-
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
-
-
-
-
-
-
-
Immunome Reports Third Quarter 2023 Financial Results
-
-
-
-
-
-
-
Immunome Reports First Quarter 2023 Financial Results
-
-
-
-
-
-
-
Immunome Reports Third Quarter 2022 Financial Results
-
326,488 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

